Monitor the May 14 investor meeting for new biomarker and immunologic data on soquelitinib, which could influence investor sentiment ahead of the Phase 3 readout in PTCL. Absence of a Q1 earnings call suggests limited near-term financial updates.
CRVS drugs
CRVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 21 $17.14entry
- T+1 · 7mo ago +4.14%α +3.12% · $17.85
- T+5 · 7mo ago −8.87%α −9.95% · $15.62
- T+20 · 6mo ago −28.76%α −33.68% · $12.21
- T+60 · 4mo ago −16.74%α −23.64% · $14.27
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Corvus Pharmaceuticals will host an investor meeting on May 14, 2026, to highlight new Phase 1 clinical data for soquelitinib in atopic dermatitis, including late-breaking data on drug-free remissions, presented at the Society for Investigative Dermatology meeting. The company will report Q1 2026 financial results on May 7 but will not hold a conference call.
Key Facts
- Investor and analyst meeting scheduled for May 14, 2026, to discuss soquelitinib Phase 1 data from the SID Annual Meeting.
- Two oral presentations at SID include a late-breaking session on drug-free remissions with soquelitinib.
- Phase 1 trial data is from a randomized, blinded, placebo-controlled study in moderate-to-severe atopic dermatitis.
- Company to release Q1 2026 financial results on May 7, 2026, without a conference call or webcast.
- Soquelitinib is an oral, selective ITK inhibitor currently in Phase 3 for relapsed/refractory PTCL and Phase 2 for atopic dermatitis.
Financial Impact
No financial data disclosed in this release; financial results expected May 7.
Risk Factors
- Clinical data may not translate into meaningful efficacy in later-stage trials.
- No conference call for Q1 results may limit transparency and investor engagement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277804 |
Track record
15 reports on CRVS
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
- Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
- Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
- Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
- May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers